Invega Sustenna is a long-acting injectable antipsychotic medication prescribed for the treatment of schizophrenia and schizoaffective disorder [1][2]. It is administered intramuscularly by a healthcare professional [2].
How does Invega Sustenna work?
Invega Sustenna contains paliperidone palmitate, which is a prodrug of paliperidone [3]. Once injected, paliperidone palmitate is slowly hydrolyzed in the body to release paliperidone. Paliperidone is an atypical antipsychotic that works by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain [3]. This action is believed to help manage the symptoms of psychosis, such as hallucinations and delusions [2].
How is Invega Sustenna administered?
Invega Sustenna is given as an intramuscular injection [2]. The initial dose typically involves two separate injections administered on the same day [4]. Subsequent injections are given monthly [2]. The injection site and needle size may vary depending on the dose [4].
What is the difference between Invega Sustenna and Invega?
Invega Sustenna is the long-acting injectable formulation of paliperidone, while Invega is the oral tablet formulation [1][3]. Invega Sustenna provides a sustained release of the medication over one month, whereas the oral Invega requires daily dosing [2][3]. This difference is significant for patients who may have difficulty adhering to a daily medication schedule [2].
When does the patent for Invega Sustenna expire?
Patent information for Invega Sustenna can be complex and may involve multiple patents covering the drug substance, formulations, and methods of use [5]. DrugPatentWatch.com tracks these patents, which are crucial for understanding when generic versions might become available [5]. The listed patents for paliperidone palmitate, the active ingredient in Invega Sustenna, have expiration dates that extend into the future, indicating ongoing market exclusivity [5].
What are the common side effects of Invega Sustenna?
Common side effects reported with Invega Sustenna include weight gain, drowsiness or sedation, dizziness, headache, and involuntary movements such as akathisia (restlessness) or extrapyramidal symptoms [2][6]. Other potential side effects include dry mouth, constipation, and injection site reactions [2]. It is important for patients to discuss any concerns about side effects with their healthcare provider [2].
Who makes Invega Sustenna?
Invega Sustenna is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1].
What are the risks associated with Invega Sustenna?
Like other antipsychotic medications, Invega Sustenna carries significant risks. These include a potential for tardive dyskinesia, a serious movement disorder that may be irreversible, and neuroleptic malignant syndrome, a rare but potentially fatal condition characterized by high fever, muscle rigidity, and changes in mental status [2][6]. There is also a warning about increased mortality in elderly patients with dementia-related psychosis, though Invega Sustenna is not indicated for this use [2][6]. Patients should be closely monitored for these risks [2].
Are there alternative treatments for schizophrenia and schizoaffective disorder?
Yes, alternative treatments include other oral and long-acting injectable antipsychotics from various manufacturers [7]. These alternatives may differ in their mechanisms of action, side effect profiles, and dosing schedules [7]. The choice of treatment is individualized based on the patient's specific condition, medical history, and response to therapy [2][7].
Can generic versions of Invega Sustenna be made?
The availability of generic versions of long-acting injectable medications like Invega Sustenna depends on the expiration of relevant patents and any exclusivity periods granted by regulatory agencies [5]. As patents expire, other pharmaceutical companies may seek to develop and market generic paliperidone palmitate injectable products [5].
Sources:
[1] https://www.drugpatentwatch.com/drugs/invega-sustenna
[2] https://www.invegasustenna.com/
[3] https://www.rxlist.com/invega-sustenna-side-effects-drug-center.htm
[4] https://www.drugs.com/dosage/invega-sustenna.html
[5] https://www.drugpatentwatch.com/paliperidone-palmitate/patents
[6] https://www.mayoclinic.org/drugs-supplements/paliperidone-palmitate-injection-route/proper-use/dr-20068218
[7] https://www.nami.org/About-Mental-Illness/Treatments/Medications